Other Events ·
Inhibrx reports INBRX-106 cORR of 48.3% versus 26.5% in head and neck cancer, plans FDA meeting
INBXInhibrx Biosciences, Inc.
Inhibrx Biosciences posted an updated corporate presentation on September 28, 2026, detailing clinical data for its pipeline candidates. For INBRX-106 (ozekibart), the company reported interim results from the HexAgon study in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The combination of INBRX-106 with pembrolizumab demonstrated a confirmed objective response rate (cORR) of 48.3% versus 26.5% for pembrolizumab alone, with median progression-free survival of 9.6 months compared to 4.9 months. In HPV-positive patients, cORR reached 80% versus 33%, and the Phase 2 portion is expanding to include 50 additional HPV+ patients to pursue an accelerated approval path by late 2028 or early 2029. For INBRX-109 (ozekibart), registrational data in chondrosarcoma showed a median progression-free survival of 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479. The company also plans to meet with the FDA regarding colorectal cancer trial design and presented preclinical glioblastoma data. Inhibrx Biosciences operates in the biotechnology industry, focusing on discovering and developing novel protein-engineered biologics for oncology.